The hard clinical context related to the age-related macular degeneration or maculopathy, chronic ocular disease and first cause of blindness in developed countries, has to be solved. 

The number of affected patients is increasing drastically with 500'000 new cases per year and a pool of 260 million patients is estimated for 2040. 

Despite the noted efficacy of the drug, the intravitreal injections to which patients are subjected monthly implies a high rate of treatment dropout, followed by a very high risk of irreversible blindness condition.
____________________________________________________________

MgShell is developing an innovative game changer in the treatment space, an intraocular device able to replicate the current clinical strategy reducing drastically the number of intravitreal injections and all the therapeutical burdens.

Our device represents the only technological solution able to replicate the current clinical practice with a single injection and release the same therapeutical drug doses in preset times, in an autonomous way and without surgical procedures.
    
We offer a product as a result of a win-win-win philosophy: we do compliance for affected patients, we do decrease of overheads for Healthcare systems, and we do business for pharmaceutical companies.

Health Care

Life Sciences

Medical Devices

Therapeutics

MgShell S.r.l.

Milano 3 is likely focused on research and development within the clinical and scientific sectors.

MgShell S.r.l.

Org chart

Teams

Offices

MgShell S.r.l.

Org chart

Teams

Offices

Related companies